The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Pork - I think it is all about volume of interest in the SP. SO would be done tomorrow if a big enough buyer was that much in but it'll take as long as you same if demand stays as it is. Lets hope results change the landscape. KR
@Hopeingmore
If you could back off from crl123 please, you have no idea what is going on in others lives.
Besides, sang changes his position more times than his underpants. When he is short or out, he is reminding us all of the negatives and being a royal pain in the arse and when he is long or buying back in he is suddenly positive.
He brought back in on the 24th hence positive .... for now.
However, much as i want this to recover we are possibly looking at another 10 weeks before SO is completely out. The fund continues to sell into the gains. Its about 1% every two and a half weeks. Once that's done its onwards and upwards.
If the data readouts come earlier then that might push us up and he can clear his position quicker if that's what he wants to do, GLA
More bile from crl123
Sangijuelas
I , like robins, am confused.
You were almost ****ging 4D off only a month ago ( ?!?)
It's basically an hour long advert for ivermectin.
I have been recommended this channel by some respected immunologists.
https://m.youtube.com/playlist?list=PLFs4vir_WsTyY31efyHdmtp9l7DpR0Wvi
They have a book as well
https://www.waterstones.com/book/immune/philipp-dettmer/9781529360684
Cheers Sang, my mate who is a Senior Lecturer in Nursing put me on to him. He is from "up north" like all myself and my wife's family so he sounds all right to me. He did get into trouble for saying Ivermectin could have helped in Japan. Appreciate any other sources that could be better, thanks
I think it's really sad that you are looking to John Campbell for your science.
I have heard about him spreading covid disinformation. I listened to about 30 seconds of the video and stopped when he mentioned the gut-lung ACCESS as opposed to axis.
Thanks for this thread in getting back to the science. The success of this shares will I hope be determined by this.
Can I encourage the more knowledgeable on this subject to share their thoughts.
I just watched Dr John Thomson and Professor Clancy on YouTube talk about COVID and the importance of the gut and our Peyer's patch in our immune system.
Has anyone got any recommendations on similar videos to help the uneducated on the science. Thanks
Sang just my opinion but you are so positive at the moment of our prospects but you have been negative in the recent past. Do not ask me to recall your past texts but I am not sure where you think we are going.
We are at a point where medicine is starting to understand how to unlock the potential of our immune system and help it fight diseases we currently consider incurable.
Just a reminder that before the antibiotics came along a serious bacterial infection meant patient was likely to die.
Microbiome is a brand new drug class. It potentially could be as big (if not bigger) than, for instance, antibiotics.
And based on the trials so far I don't think we are too far away from a potential breakthrough. Clearly big pharma think so to - otherwise why invest in companies like 4D and hire people responsible for Microbiome R&D and M&A functions.
We just need some positive data. Just my opinion guys, do your own DD. GLA
Quote from the article
"If you are able to take out or partially take out the regulatory T cells from the equation, it’s like moving a rock up the mountain, where you will be able to push the boulder down and initiate a cascade of events that will end up in tumour rejection. So, for us, it’s one of the holy grails of immune regulation that if you target properly, you can get tumour control."
Interesting article on Tregs significance from the Professor behind the Tusk/Roche drug.
https://www.ucl.ac.uk/news/2020/nov/interview-developing-new-immunotherapy-gain-control-cancer
People mocked Woodford but already one of his unlisted portfolio companies Oxford Nanopore is now valued at over £4bn
That's an idea of the potential value on the table here.
Roche bought Tusk for nearly $800m for a drug that was still emerging from pre clinical development.
4D is already half way through P2 with no adverse effects likely due to its safety profile.
Immune Checkpoint Inhibitors (ICIs) work in a fairly small group of patients 20-35% depending on the therapy and the form of cancer. And in about half of these responders after a while they stop working usually as a result of immune system exhaustion.
One important way ICIs can stop working is when resistance to them is acquired due to excessive Tregs which suppress the anti tumour response.
"Achieving depletion of regulatory T cells while sparing tumor-specific effector T cells has long remained an elusive goal of immunotherapy" .
https://www.nature.com/articles/s43018-020-00155-8
The biomarker data from Part A of 4Ds MRX 0518/Keytruda trial showed that responders had higher ratios of Tregs to tumour killing cells in the tumour.
MRx0518 works by suppressing Tregs and making cancer killing cells proliferate.
There are various ways being studied to achieve Treg depletion and it is a major goal of Big Pharma. Most of these efforts are in the very early stages, or have had inconclusive results or have been shown to have toxicity issues.
An example of one is the anti CD25 monoclonal antibody developed by Tusk Therapeutics. Roche bought Tusk for $759m and they only have it as a P1 trial application.
Getting more conclusive data from Part B of the 0518 trial would represent a major medical and scientific breakthrough in the field of ICIs.